Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency
Samaneh Delavari, Hassan Abolhassani, Farhad Abolnezhadian, Fateme Babaha, Sara Iranparast, Hamid Ahanchian, Nasrin Moazzen, Mohammad Nabavi, Saba Arshi, Morteza Fallahpour, Mohammad Hassan Bemanian, Sima Shokri, Tooba Momen, Mahnaz Sadeghi‐Shabestari, Rasol Molatefi, Afshin Shirkani, Ahmad Vosughimotlagh, Molood Safarirad, Meisam Sharifzadeh, Salar Pashangzadeh, Fereshte Salami, Paniz Shirmast, Arezou Rezaei, Tannaz Moeini Shad, Minoo Mohraz, Nima Rezaei, Lennart Hammarström, Reza Yazdani, Asghar Aghamohamamdi
Abstract
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.